---
title: "Mounjaro (tirzepatide) in type 2 diabetes: Specific populations questions"
description: "Specific populations questions on Mounjaro (tirzepatide) in type 2 diabetes, each answered with verbatim quotes from the manufacturer's US website for healthcare professionals or documents it links. Questions: At what age can children take Mounjaro? Is Mounjaro safe and effective for adults 65 and older? 2 questions quoted from 2 sources."
canonical: "https://www.evicenter.com/medical-information/mounjaro--type-2-diabetes/specific-populations"
published: "2026-11-12T22:05:36-05:00"
modified: "2026-11-14T16:49:54-05:00"
---

# Mounjaro (tirzepatide) in type 2 diabetes: Specific populations questions

Manufacturer: Lilly USA, LLC  
Prescribing information: [Mounjaro](https://uspl.lilly.com/mounjaro/mounjaro.html#pi)

Specific populations questions that apply to every indication of Mounjaro are on [Mounjaro (tirzepatide), all indications: Specific populations](https://www.evicenter.com/medical-information/mounjaro/specific-populations).

## Specific populations

<a id="mounjaro-children-age"></a>

### At what age can children take Mounjaro?

Applies to: Glycemic control as an adjunct to diet and exercise in pediatric patients 10 years of age and older with type 2 diabetes mellitus

> “Mounjaro is approved for pediatric patients 10 years of age and older with type 2 diabetes as an adjunct to diet and exercise to improve glycemic control.”

Source: [MOUNJARO: PEDs, captured 2026-11-12](https://mounjaro.lilly.com/hcp/peds#:~:text=Mounjaro%20is%20approved%20for%20pediatric,exercise%20to%20improve%20glycemic%20control.)

> “The safety and effectiveness of MOUNJARO as an adjunct to diet and exercise to improve glycemic control in pediatric patients 10 years of age and older with type 2 diabetes mellitus have been established. Use of MOUNJARO for this indication is supported by a 30-week, randomized, double-blind, placebo-controlled trial with a 22-week open label extension in 99 pediatric patients [see Clinical Studies (14.5)].”

Source: [MOUNJARO: Prescribing information, captured 2026-11-12](https://uspl.lilly.com/mounjaro/mounjaro.html#pi:~:text=The%20safety%20and%20effectiveness%20of,patients%20%5Bsee%20Clinical%20Studies%20%2814.5%29%5D.)

> “The safety and effectiveness of MOUNJARO have not been established in pediatric patients less than 10 years of age.”

Source: [MOUNJARO: Prescribing information, captured 2026-11-12](https://uspl.lilly.com/mounjaro/mounjaro.html#pi:~:text=The%20safety%20and%20effectiveness%20of%20MOUNJARO%20have,than%2010%20years%20of%20age.)

> “MOUNJARO KwikPen is not recommended for self-administration by pediatric patients.”

Source: [MOUNJARO: Prescribing information, captured 2026-11-12](https://uspl.lilly.com/mounjaro/mounjaro.html#pi:~:text=MOUNJARO%20KwikPen%20is%20not%20recommended%20for%20self%2Dadministration%20by%20pediatric%20patients.)

<a id="mounjaro-older-adults"></a>

### Is Mounjaro safe and effective for adults 65 and older?

Applies to: Glycemic control as an adjunct to diet and exercise in adults with type 2 diabetes mellitus

> “In the pool of seven clinical trials, 1,539 (30.1%) MOUNJARO-treated patients were 65 years of age or older, and 212 (4.1%) MOUNJARO-treated patients were 75 years of age or older at baseline [see Adverse Reactions (6.1), Clinical Studies (14.2, 14.3, 14.4)].”

Source: [MOUNJARO: Prescribing information, captured 2026-11-12](https://uspl.lilly.com/mounjaro/mounjaro.html#pi:~:text=In%20the%20pool%20of%20seven%20clinical%20trials%2C%201%2C539,Clinical%20Studies%20%2814.2%2C%2014.3%2C%2014.4%29%5D.)

> “No overall differences in safety or effectiveness of MOUNJARO have been observed between patients 65 years of age and older and younger adult patients.”

Source: [MOUNJARO: Prescribing information, captured 2026-11-12](https://uspl.lilly.com/mounjaro/mounjaro.html#pi:~:text=No%20overall%20differences%20in%20safety,older%20and%20younger%20adult%20patients.)

## Related pages
- [Medical information: Mounjaro (tirzepatide): Type 2 diabetes](https://www.evicenter.com/medical-information/mounjaro--type-2-diabetes)
- [Indication](https://www.evicenter.com/medical-information/mounjaro--type-2-diabetes/indication)
- [Clinical trials](https://www.evicenter.com/medical-information/mounjaro--type-2-diabetes/clinical-trials)
- [Safety](https://www.evicenter.com/medical-information/mounjaro--type-2-diabetes/safety)
- [Dosing and administration](https://www.evicenter.com/medical-information/mounjaro--type-2-diabetes/dosing-and-administration)
- [Access and coverage](https://www.evicenter.com/medical-information/mounjaro--type-2-diabetes/access-and-coverage)
